African Jounal of Perinatology vol.2 issue 2 de Mai-Août 2025 P:(95-105)

Innovative approaches to managing pediatric hematologic malignancies: clinical and translational perspectives

*Emmanuel Ifeanyi Obeagu

Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

**Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe, E-mail: emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161, +2348037369912*

Abstract

Pediatric hematologic malignancies, encompassing acute leukemias, lymphomas, and rare myelodysplastic syndromes, remain a leading cause of childhood morbidity and mortality worldwide. Over the past decade, rapid advancements in molecular biology, immunotherapy, and gene-editing technologies have revolutionized diagnostic, prognostic, and therapeutic strategies. This narrative review explores innovative clinical and translational approaches in pediatric hematologic malignancies, highlighting precision medicine, novel pharmacologic interventions, immunotherapeutic modalities, and integrative strategies that bridge laboratory discoveries to bedside care. Emphasis is placed on recent breakthroughs in chimeric antigen receptor (CAR) T-cell therapy, targeted small-molecule inhibitors, and gene therapy, as well as challenges in implementation, including accessibility, safety, and long-term outcomes. By synthesizing current evidence, this review provides a framework for clinicians and researchers seeking to optimize patient-centered care and accelerate translational progress in pediatric hematology.

Keywords: Pediatric hematology, Hematologic malignancies, Precision medicine, Gene therapy, Translational research.

Introduction

Pediatric hematologic malignancies, encompassing acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), lymphomas, and rare myelodysplastic syndromes, represent a significant global health challenge, accounting for a substantial proportion of childhood cancers and associated mortality. Over the past several decades, survival rates have improved dramatically, largely due to risk-adapted chemotherapy protocols, supportive care advances, and enhanced diagnostic capabilities. Despite these advances, a subset of children continues to experience refractory disease, early relapse, or long-term therapy-related toxicities, underscoring the need for innovative therapeutic strategies that go beyond conventional approaches [1-2]. The last decade has witnessed a paradigm shift in pediatric hematology, driven by advances in molecular biology, genomics, and immunology. Precision medicine, which tailors treatment based on individual genetic and molecular profiles, has emerged as a cornerstone in optimizing outcomes. Molecular profiling techniques, including next-generation sequencing (NGS) and single-cell analyses, have enabled the identification of specific driver mutations,

epigenetic alterations, and prognostic biomarkers, facilitating more targeted and less toxic interventions [3-4].

Concurrently, immunotherapy has transformed the therapeutic landscape. Chimeric antigen receptor (CAR) T-cell therapies, bispecific T-cell engagers (BiTEs), and checkpoint inhibitors have demonstrated unprecedented efficacy in refractory and relapsed pediatric hematologic malignancies. These strategies leverage the patient's immune system to selectively target malignant cells, offering the potential for durable remissions where conventional chemotherapy may fail [5]. Gene therapy and genome-editing technologies, particularly CRISPR/Cas9-based approaches, represent another frontier in pediatric hematology. By correcting genetic defects or modulating immune responses, these interventions offer the potential for long-term disease control and even functional cures. Translational research efforts are critical in bridging laboratory discoveries to clinical implementation, addressing challenges such as off-target effects, immunogenicity, and equitable access [6-7].

Despite these promising innovations, significant challenges remain. Therapy-related toxicities, high treatment costs, limited access in low-resource settings, and the need for long-term follow-up studies pose barriers to widespread implementation. Nevertheless, ongoing clinical trials and translational initiatives continue to expand the therapeutic arsenal, providing hope for improved survival, quality of life, and functional outcomes in children with hematologic malignancies [8]. This narrative review synthesizes recent advances in clinical and translational strategies for managing pediatric hematologic malignancies, highlighting molecular and genomic innovations, targeted pharmacologic therapies, immunotherapy, and gene-based interventions. By integrating current evidence, this review aims to provide a comprehensive framework for clinicians, researchers, and stakeholders seeking to optimize patient-centered care and accelerate the translation of laboratory discoveries into clinical practice (Table 1).

Table 1: Selected Molecular and Targeted Therapies in Pediatric Hematologic Malignancies

Disease/Subtype	Molecular Target / Pathway	Therapeutic Approach	Clinical Impact / Notes
B-cell ALL (Ph+)	BCR-ABL1 fusion	Tyrosine kinase inhibitors (Imatinib, Dasatinib)	Improved survival, reduced relapse risk
Ph-like ALL	Kinase-activating alterations	TKIs (Ruxolitinib, Dasatinib)	Targeted therapy in high-risk subgroups
AML	FLT3 mutation	FLT3 inhibitors (Midostaurin, Gilteritinib)	Improved remission rates, used with chemotherapy
AML	IDH1/2 mutation	IDH inhibitors (Enasidenib, Ivosidenib)	Reduces leukemic proliferation in select patients

ALL / AML	Epigenetic dysregulation	HDAC inhibitors, DNMT inhibitors	Promotes apoptosis/differentiation, under clinical investigation
B-cell ALL	CD19 antigen	CAR T-cell therapy	High remission in refractory/relapsed disease
B-cell ALL	CD3/CD19	BiTEs (Blinatumomab)	Redirects T cells to leukemic cells, bridge to transplant
Various leukemias	Immune checkpoints (PD-1/PD-L1, CTLA-4)	Checkpoint inhibitors	Enhances anti-tumor immunity, investigational in pediatrics
Leukemia predisposition syndromes	Genetic defects (e.g., Fanconi anemia)	Gene therapy / CRISPR-Cas9	Corrects underlying defect, experimental and translational

Molecular and Genomic Innovations

The advent of molecular and genomic technologies has fundamentally transformed the understanding and management of pediatric hematologic malignancies. Traditional classification systems based on morphology and immunophenotype have increasingly been complemented, and in some cases supplanted, by molecular profiling, which provides critical insights into the underlying biology of disease, informs prognosis, and guides targeted therapy.

Genomic Profiling in Pediatric Leukemias: In pediatric acute lymphoblastic leukemia (ALL), genomic characterization has revealed a spectrum of molecular subtypes with distinct prognostic implications. For example, Philadelphia chromosome-like (Ph-like) ALL is characterized by kinase-activating alterations and is associated with high relapse risk, prompting exploration of tyrosine kinase inhibitors as adjunctive therapy. Similarly, in acute myeloid leukemia (AML), recurrent mutations in genes such as FLT3, NPM1, and CEBPA have informed risk stratification and the use of targeted inhibitors. Whole-genome and exome sequencing have enabled the identification of novel oncogenic drivers and rare fusion genes, providing opportunities for precision-directed interventions [9-10].

Single-Cell and Epigenomic Analyses: Single-cell RNA sequencing (scRNA-seq) has provided unprecedented resolution in delineating intratumoral heterogeneity, revealing subpopulations of leukemic cells that may drive relapse and treatment resistance. Coupled with epigenomic analyses—examining DNA methylation, histone modifications, and chromatin accessibility—these techniques elucidate mechanisms of transcriptional dysregulation and identify epigenetic vulnerabilities that can be therapeutically exploited [12-13].

Predictive Biomarkers and Risk Stratification: Molecular profiling has enabled the development of predictive biomarkers for therapy response and relapse risk. Minimal residual disease (MRD) monitoring, often guided by molecular assays, is now a standard tool in pediatric leukemia management, providing real-time insights into treatment efficacy and facilitating early intervention in high-risk patients. Furthermore, integrating mutational data with cytogenetic and immunophenotypic information allows for

refined risk-adapted therapy, minimizing exposure to intensive chemotherapy in low-risk patients while intensifying treatment for high-risk cohorts [13].

Translational Implications: The identification of actionable molecular targets has catalyzed the development of precision therapies in pediatric hematology. Tyrosine kinase inhibitors, FLT3 inhibitors, and BCL-2 antagonists exemplify targeted agents that have transitioned from bench to bedside. Additionally, molecular diagnostics have informed eligibility for clinical trials, enabling the evaluation of novel therapies in genetically defined patient subgroups [14].

Molecular and Genomic Innovations

The advent of molecular and genomic technologies has fundamentally transformed the understanding and management of pediatric hematologic malignancies. Traditional classification systems based on morphology and immunophenotype have increasingly been complemented, and in some cases supplanted, by molecular profiling, which provides critical insights into the underlying biology of disease, informs prognosis, and guides targeted therapy.

Genomic Profiling in Pediatric Leukemias: In pediatric acute lymphoblastic leukemia (ALL), genomic characterization has revealed a spectrum of molecular subtypes with distinct prognostic implications. For example, Philadelphia chromosome-like (Ph-like) ALL is characterized by kinase-activating alterations and is associated with high relapse risk, prompting exploration of tyrosine kinase inhibitors as adjunctive therapy. Similarly, in acute myeloid leukemia (AML), recurrent mutations in genes such as FLT3, NPM1, and CEBPA have informed risk stratification and the use of targeted inhibitors. Whole-genome and exome sequencing have enabled the identification of novel oncogenic drivers and rare fusion genes, providing opportunities for precision-directed interventions [15-16].

Single-Cell and Epigenomic Analyses: Single-cell RNA sequencing (scRNA-seq) has provided unprecedented resolution in delineating intratumoral heterogeneity, revealing subpopulations of leukemic cells that may drive relapse and treatment resistance.

Targeted Pharmacologic Approaches

Coupled with epigenomic analyses—examining DNA methylation, histone modifications, and chromatin accessibility—these techniques elucidate mechanisms of transcriptional dysregulation and identify epigenetic vulnerabilities that can be therapeutically exploited [17].

Predictive Biomarkers and Risk Stratification: Molecular profiling has enabled the development of predictive biomarkers for therapy response and relapse risk. Minimal residual disease (MRD) monitoring, often guided by molecular assays, is now a standard tool in pediatric leukemia management, providing real-time insights into treatment efficacy and facilitating early intervention in high-risk patients. Furthermore, integrating mutational data with cytogenetic and immunophenotypic information allows for refined risk-adapted therapy, minimizing exposure to intensive chemotherapy in low-risk patients while intensifying treatment for high-risk cohorts [18].

Translational Implications: The identification of actionable molecular targets has catalyzed the development of precision therapies in pediatric hematology. Tyrosine kinase inhibitors, FLT3 inhibitors, and BCL-2 antagonists exemplify targeted agents that have transitioned from bench to bedside. Additionally, molecular diagnostics have informed eligibility for clinical trials, enabling the evaluation of novel therapies in genetically defined patient subgroups [19].

The translation of molecular insights into targeted pharmacologic strategies has revolutionized the management of pediatric hematologic malignancies. Whereas traditional chemotherapy broadly attacks rapidly dividing cells, targeted therapies exploit specific genetic, signaling, or metabolic vulnerabilities in malignant cells, enhancing efficacy while reducing systemic toxicity.

Kinase and Signaling Pathway Inhibitors: Aberrant activation of signaling pathways is a hallmark of many pediatric hematologic malignancies. Tyrosine kinase inhibitors (TKIs), such as dasatinib and imatinib, have demonstrated efficacy in Philadelphia chromosome-positive (Ph+) ALL, transforming previously high-risk disease into a manageable condition. In AML, FLT3 inhibitors (e.g., midostaurin, gilteritinib) target constitutively activated kinases, while IDH1/2 inhibitors exploit metabolic vulnerabilities in specific leukemic subtypes. By directly interfering with oncogenic signaling, these agents provide precision-based alternatives or adjuncts to conventional chemotherapy [20-21].

Epigenetic and Proteasome-Targeted Agents: Pediatric leukemias frequently exhibit epigenetic dysregulation, including aberrant DNA methylation and histone modification. Histone deacetylase (HDAC) inhibitors and DNA methyltransferase (DNMT) inhibitors can reverse transcriptional silencing of tumor suppressor genes, promoting apoptosis and differentiation. Proteasome inhibitors, such as bortezomib, exploit vulnerabilities in protein homeostasis, particularly in lymphoid malignancies, offering an additional mechanism to enhance cytotoxicity [22].

Rational Combination Therapies: Targeted agents are increasingly employed in combination with conventional chemotherapy or other targeted drugs to maximize synergistic effects and overcome resistance. For instance, combining TKIs with corticosteroids or multi-agent chemotherapy has shown superior outcomes in high-risk ALL subgroups. Similarly, pairing BCL-2 inhibitors with cytotoxic therapy can enhance apoptosis in resistant AML clones. Such combinatorial strategies are guided by molecular profiling, ensuring therapy is personalized to the patient's tumor biology [23].

Clinical Implications and Challenges: While targeted pharmacologic approaches offer substantial benefits, challenges remain. Resistance mechanisms, such as secondary mutations in target genes or activation of alternative signaling pathways, can limit durability of response. Additionally, long-term toxicity profiles in children require careful monitoring, and high costs may restrict access in resource-limited settings. Ongoing clinical trials are critical to optimize dosing, sequencing, and combination strategies while evaluating safety and efficacy in diverse pediatric populations [24].

Immunotherapy Innovations

Immunotherapy has emerged as a transformative approach in the management of pediatric hematologic malignancies, harnessing the patient's immune system to selectively target malignant cells. Unlike conventional chemotherapy, which indiscriminately affects dividing cells, immunotherapeutic strategies offer precision, potential durability of response, and the ability to overcome resistance mechanisms.

Chimeric Antigen Receptor (CAR) T-Cell Therapy: CAR T-cell therapy has revolutionized the treatment landscape for relapsed or refractory pediatric B-cell acute lymphoblastic

leukemia (B-ALL). Patient-derived T cells are genetically engineered to express receptors targeting specific tumor antigens, most commonly CD19. Clinical studies have reported remarkable complete remission rates, even in heavily pretreated children, highlighting the potential for durable disease control. Ongoing research aims to optimize CAR design, minimize cytokine release syndrome (CRS) and neurotoxicity, and expand applicability to other hematologic malignancies, including AML and T-cell leukemias [25].

Bispecific T-Cell Engagers (BiTEs): BiTEs are engineered antibodies that simultaneously bind T cells and tumor-associated antigens, redirecting endogenous cytotoxic T cells to malignant cells. Blinatumomab, a CD3/CD19 BiTE, has demonstrated efficacy in pediatric B-ALL, offering a non-cell-based immunotherapeutic alternative to CAR T-cell therapy. These agents provide rapid anti-leukemic responses and may serve as bridging therapy to hematopoietic stem cell transplantation [26].

Checkpoint Inhibitors: Immune checkpoint inhibitors, targeting PD-1, PD-L1, and CTLA-4 pathways, aim to overcome tumor-mediated immune evasion. While their use in pediatric hematologic malignancies is still investigational, early studies suggest potential benefits in combination with other therapies. Checkpoint blockade may enhance anti-tumor immunity, particularly in refractory disease or post-transplant relapse, though pediatric-specific safety and dosing considerations remain areas of active investigation [27].

Emerging Cellular and Immune Modulatory Approaches: Beyond CAR T-cells and BiTEs, novel strategies such as natural killer (NK) cell therapy, tumor-infiltrating lymphocyte expansion, and engineered cytokine therapies are being explored in pediatric populations. These approaches aim to enhance immune-mediated cytotoxicity, modulate the tumor microenvironment, and reduce immunotherapy-related toxicities [28].

Gene Therapy and Translational Strategies

Gene therapy represents one of the most promising frontiers in pediatric hematologic malignancies, offering the potential to correct underlying genetic defects, enhance anti-tumor immunity, and achieve durable remissions. Unlike conventional chemotherapy or even targeted therapies, gene-based interventions aim to address disease at its molecular root, providing opportunities for functional cures.

Ex Vivo Gene Editing: Advances in CRISPR/Cas9 and other genome-editing technologies have enabled precise modification of hematopoietic stem cells (HSCs) and T cells. In pediatric leukemias, gene editing can be used to enhance the efficacy of CAR T-cell therapies by improving persistence, reducing exhaustion, or knocking out inhibitory receptors. Ex vivo modification of HSCs also holds promise for inherited hematologic disorders that predispose children to malignancy, such as Fanconi anemia or certain congenital bone marrow failure syndromes [29].

Viral Vector-Mediated Gene Delivery: Lentiviral and retroviral vectors are widely used to introduce therapeutic genes into patient-derived cells. Clinical trials have demonstrated the feasibility of reprogramming HSCs or T cells to express anti-tumor receptors, cytokines, or suicide genes that allow controlled elimination of modified cells if adverse events occur. This strategy enables precise, durable, and controllable therapeutic interventions [30].

Integration with Immunotherapy: Gene therapy is increasingly combined with immunotherapeutic approaches to enhance efficacy. For example, CAR T cells modified with gene-editing tools can overcome tumor-mediated immune evasion or resist exhaustion, increasing the likelihood of sustained remission. Similarly, engineered T cells may be designed to secrete cytokines or checkpoint modulators to improve anti-leukemic activity [31].

Translational Research and Clinical Implementation: Translational strategies are essential to bridge laboratory discoveries to clinical care. Preclinical studies guide vector design, optimize gene-editing techniques, and identify potential toxicities. Early-phase clinical trials assess safety, efficacy, and long-term persistence of gene-modified cells. Integration with molecular diagnostics and risk stratification ensures that interventions are tailored to the genetic and immunologic profile of individual patients (Table 2) [32]

Table 2: Key Challenges and Future Directions in Pediatric Hematologic Malignancy Innovations

Innovation Area	*Clinical Benefits*	*Challenges / Limitations*	*Future Directions*
Molecular and Genomic Profiling	*Precision diagnosis, risk stratification, therapy guidance*	*High cost, limited access, interpretation complexity*	*Broader accessibility, AI-assisted analysis, expanded biomarker discovery*
Targeted Pharmacologic Therapy	*Reduced systemic toxicity, improved efficacy*	*Resistance development, long-term side effects, limited pediatric-specific data*	*Rational drug combinations, pediatric-optimized dosing, novel small molecules*
Immunotherapy (CAR T, BiTEs, Checkpoint inhibitors)	*Durable remissions, treatment of refractory disease*	*CRS, neurotoxicity, antigen escape, infrastructure demands*	*Safer CAR designs, off-the-shelf products, predictive biomarkers for toxicity*
Gene Therapy / Gene Editing	*Potential for functional cure, addresses root cause*	*Off-target effects, immunogenicity, long-term safety unknown, high cost*	*Safer vectors, optimized CRISPR techniques, scalable manufacturing*
Translational Research Integration	*Bridges lab discoveries to clinical care*	*Regulatory hurdles, clinical trial access, limited long-term data*	*Expanded multi-center trials, global collaboration, patient-centered trial designs*

Clinical Implications and Future Directions

The integration of molecular, pharmacologic, immunotherapeutic, and gene-based innovations is fundamentally reshaping the clinical management of pediatric hematologic malignancies. These advancements enable a shift from conventional, one-size-fits-all

chemotherapy regimens to personalized, precision-guided treatment strategies, improving efficacy while minimizing toxicity.

Risk-Adapted and Precision Therapy: Molecular and genomic profiling allows clinicians to stratify patients based on genetic and epigenetic risk factors, enabling tailored therapy intensity. For example, children with low-risk genetic subtypes may avoid excessive chemotherapy, reducing long-term cardiotoxicity, growth impairment, and secondary malignancies. Conversely, high-risk patients can receive targeted pharmacologic or immunotherapeutic interventions early, improving survival outcomes [33].

Integration of Immunotherapy and Gene Therapy: The clinical availability of CAR T-cell therapy, BiTEs, and emerging gene-editing strategies provides powerful options for refractory or relapsed disease. These approaches not only offer the potential for durable remissions but also introduce novel clinical considerations, including management of cytokine release syndrome (CRS), neurotoxicity, and long-term immune modulation. Multidisciplinary care teams and specialized treatment centers are increasingly essential to safely administer and monitor these advanced therapies [34].

Translational Research and Clinical Trials: Translational research continues to drive innovation, providing a critical bridge from laboratory discoveries to bedside application. Clinical trials evaluating novel targeted agents, immune-based therapies, and gene-modified cellular products are expanding treatment options and informing best practices. These studies also provide opportunities to identify biomarkers predictive of response, toxicity, and long-term outcomes, further refining precision medicine strategies [35].

Challenges and Equity Considerations: Despite significant progress, challenges remain. High costs, need for specialized infrastructure, and limited access in low-resource settings threaten equitable implementation. Long-term monitoring for therapy-related adverse effects, secondary malignancies, and growth or developmental complications is essential. Addressing these challenges requires global collaboration, capacity building, and the development of cost-effective, scalable interventions [36].

Conclusion

Innovative approaches in pediatric hematologic malignancies—including molecular and genomic profiling, targeted pharmacologic therapies, immunotherapy, and gene-based interventions—are transforming the landscape of care. These strategies enable precision-guided, individualized treatment, improving survival outcomes while minimizing toxicity and long-term complications. Translational research has been pivotal in bridging laboratory discoveries to clinical practice, fostering the development of novel, effective therapies. Despite significant progress, challenges such as therapy-related toxicity, high costs, limited access in resource-constrained settings, and the need for long-term follow-up remain. Addressing these barriers will require continued interdisciplinary collaboration, global equity initiatives, and ongoing clinical research.

References

1. Izraeli S. Pediatric acute leukemias and myelodysplastic syndromes, progress and challenges: introduction to a review series. Haematologica. 2025;110(9):1921-1922. doi: 10.3324/haematol.2024.286783.

2. Tseng S, Lee ME, Lin PC. A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment. Pharmaceuticals(Basel). 2023;16(11):1614. doi: 10.3390/ph16111614.

3. George SL, Izquierdo E, Campbell J, Koutroumanidou E, Proszek P, Jamal S, Hughes D, Yuan L, Marshall LV, Carceller F, Chisholm JC, Vaidya S, Mandeville H, Angelini P, Wasti A, Bexelius T, Thway K, Gatz SA, Clarke M, Al-Lazikani B, Barone G, Anderson J, Tweddle DA, Gonzalez D, Walker BA, Barton J, Depani S, Eze J, Ahmed SW, Moreno L, Pearson A, Shipley J, Jones C, Hargrave D, Jacques TS, Hubank M, Chesler L. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. Eur J Cancer. 2019; 121:224-235.doi: 10.1016/j.ejca.2019.07.027.

4. Suthapot P, Chiangjong W, Chaiyawat P, Choochuen P, Pruksakorn D, Sangkhathat S, Hongeng S, Anurathapan U, Chutipongtanate S. Genomics-Driven Precision Medicine in Pediatric Solid Tumors. Cancers (Basel). 2023;15(5):1418. doi: 10.3390/cancers15051418.

5. Zhang G, Bai M, Du H, Yuan Y, Wang Y, Fan W, Zhu H, Wu D, He P, Xue B. Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors. Immunotargets Ther. 2025; 14:655-680. doi: 10.2147/ITT.S519616.

6. Uddin F, Rudin CM, Sen T. CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. Front Oncol. 2020; 10:1387. doi: 10.3389/fonc.2020.01387.

7. Humbert O, Samuelson C, Kiem HP. CRISPR/Cas9 for the treatment of haematological diseases: a journey from bacteria to the bedside. Br J Haematol. 2021;192(1):33-49.doi: 10.1111/bjh.16807.

8. Dixon-Woods M, Amalberti R, Goodman S, Bergman B, Glasziou P. Problems and promises of innovation: why healthcare needs to rethink its love/hate relationship with the new. BMJ Qual Saf. 2011;20 Suppl 1(Suppl_1):i47-51.doi: 10.1136/bmjqs.2010.046227. PMID: 21450771; PMCID: PMC3066840.

9. Kaczmarska A, Œliwa P, Zawitkowska J, Lejman M. Genomic Analyses of Pediatric Acute Lymphoblastic Leukemia Ph+ and Ph-Like-Recent Progress in Treatment. Int J Mol Sci. 2021;22(12):6411. doi: 10.3390/ijms22126411.

10. Pui CH, Roberts KG, Yang JJ, Mullighan CG. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(8):464-470. doi: 10.1016/j.clml.2017.03.299.

11. Hu Y, Shen F, Yang X, Han T, Long Z, Wen J, Huang J, Shen J, Guo Q. Single-cell sequencing technology applied to epigenetics for the study of tumor heterogeneity. Clin Epigenetics. 2023;15(1):161. doi: 10.1186/s13148-023-01574-x.

12. Ortega-Batista A, Jaén-Alvarado Y, Moreno-Labrador D, Gómez N, García G, Guerrero EN. Single-Cell Sequencing: Genomic and

Transcriptomic Approaches in Cancer Cell Biology. Int J Mol Sci. 2025;26(5):2074. doi: 10.3390/ijms26052074.

13. Song M, Pan W, Yu X, Ren J, Tang C, Chen Z, Wang Z, Deng Y, He N, Liu H, Li S. Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment. MedComm (2020). 2025;6(6): e70193. doi: 10.1002/mco2.70193.

14. Brown P, Small D. FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. Eur J Cancer. 2004;40(5):707-21, discussion 722-4. doi: 10.1016/j.ejca.2003.08.030.

15. Kaczmarska A, Œliwa P, Zawitkowska J, Lejman M. Genomic Analyses of Pediatric Acute Lymphoblastic Leukemia Ph+ and Ph-Like-Recent Progress in Treatment. Int J Mol Sci. 2021;22(12):6411. doi: 10.3390/ijms22126411.

16. Pui CH, Roberts KG, Yang JJ, Mullighan CG. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(8):464-470. doi: 10.1016/j.clml.2017.03.299.

17. Ortega-Batista A, Jaén-Alvarado Y, Moreno-Labrador D, Gómez N, García G, Guerrero EN. Single-Cell Sequencing: Genomic and Transcriptomic Approaches in Cancer Cell Biology. Int J Mol Sci. 2025;26(5):2074. doi: 10.3390/ijms26052074.

18. Della Starza I, De Novi LA, Elia L, Bellomarino V, Beldinanzi M, Soscia R, Cardinali D, Chiaretti S, Guarini A, Foà R. Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia. Cancers (Basel). 2023;15(2):374. doi: 10.3390/cancers15020374.

19. Annesley CE, Brown P. The Biology and Targeting of FLT3 in Pediatric Leukemia. Front Oncol. 2014; 4:263. doi: 10.3389/fonc.2014.00263.

20. Jacobs CF, Eldering E, Kater AP. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Adv. 2021;5(3):913-925. doi: 10.1182/bloodadvances.2020003768.

21. Lahmouad M, Rachid Z, Bellemrrabet R, Zerrouk J, Goh KW, Bouyahya A, Aboussalah Y. Mechanisms and signaling pathways of tyrosine kinase inhibitor resistance in chronic myeloid leukemia: A comprehensive review. Leuk Res Rep. 2025; 24:100533. doi: 10.1016/j.lrr.2025.100533.

22. Xu H, Wen Y, Jin R, Chen H. Epigenetic modifications and targeted therapy in pediatric acute myeloid leukemia. Front Pediatr. 2022; 10:975819. doi: 10.3389/fped.2022.975819.

23. Victoir B, Croix C, Gouilleux F, Prié G. Targeted Therapeutic Strategies for the Treatment of Cancer. Cancers (Basel). 2024;16(2):461. doi: 10.3390/cancers16020461.

24. Lei ZN, Tian Q, Teng QX, Wurpel JND, Zeng L, Pan Y, Chen ZS. Understanding and targeting resistance mechanisms in cancer. MedComm (2020). 2023;4(3): e265. doi: 10.1002/mco2.265.

25. Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, Shademan B, Isazadeh A, Baradaran B. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy

for hematological malignancies. Cancer Med. 2023;12(7):7844-7858. doi: 10.1002/cam4.5551.

26. Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93(3):290-6. doi: 10.1038/icb.2014.93.

27. Tufail M, Jiang CH, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Ther. 2025;10(1):227. doi: 10.1038/s41392-025-02280-1.

28. Andreou T, Neophytou C, Mpekris F, Stylianopoulos T. Expanding Immunotherapy Beyond CAR T Cells: Engineering Diverse Immune Cells to Target Solid Tumors. Cancers (Basel). 2025;17(17):2917. doi: 10.3390/cancers17172917.

29. Li Y, Glass Z, Huang M, Chen ZY, Xu Q. Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications. Biomaterials. 2020; 234:119711. doi: 10.1016/j.biomaterials.2019.119711.

30. Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz). 2010;58(2):107-19. doi: 10.1007/s00005-010-0063-4.

31. Tao R, Han X, Bai X, Yu J, Ma Y, Chen W, Zhang D, Li Z. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology. Front Immunol. 2024; 15:1354825. doi: 10.3389/fimmu.2024.1354825.

32. Mahalmani V, Sinha S, Prakash A, Medhi B. Translational research: Bridging the gap between preclinical and clinical research. Indian J Pharmacol. 2022;54(6):393-396. doi: 10.4103/ijp.ijp_860_22.

33. Pratiwi L, Mashudi FH, Ningtyas MC, Sutanto H, Romadhon PZ. Genetic Profiling of Acute and Chronic Leukemia via Next-Generation Sequencing: Current Insights and Future Perspectives. Hematol Rep. 2025;17(2):18. doi: 10.3390/hematolrep17020018.

34. Zhang WY, Yang LY, Fan XX. CAR-T therapy-based innovations in the enhancement of contemporary anti-tumor therapies. Front Immunol. 2025; 16:1622433. doi: 10.3389/fimmu.2025.1622433.

35. Yu D. Translational research: current status, challenges and future strategies. Am J Transl Res. 2011;3(5):422-33.

36. Omotoso O, Teibo JO, Atiba FA, Oladimeji T, Paimo OK, Ataya FS, Batiha GE, Alexiou A. Addressing cancer care inequities in sub-Saharan Africa: current challenges and proposed solutions. Int J Equity Health. 2023;22(1):189. doi: 10.1186/s12939-023-01962-y.